Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology ...

The real drug development delay? Bad communication.

George is a professor of genetics at Harvard Medical School and professor of health sciences and technology at Harvard and MIT. He is a prolific researcher studying genetic sequencing, genome editing, ...

Erasca is spending a combined $22.5 million upfront to import fresh preclinical KRAS and molecular glue assets while clearing space in its own pipeline and laying off 18% of its employees in the ...

The comprehensive report from the bipartisan National Security Commission on Emerging Biotechnology (NSCEB) delivers a “sobering, even frightening,” conclusion: that China is quickly ascending to ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

PARIS--(BUSINESS WIRE)--Regulatory News: Acticor Biotech, (ISIN: FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of ...

Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

Will the return of biotech IPOs become the hottest fashion trend this fall? It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by ...

MINSK, 7 April (BelTA) – Deputy Prime Minister Yuri Shuleiko spoke about the economic aspects of the work of the Belarusian National Biotechnology Corporation (BNBC) after a conference hosted by the ...